<DOC>
	<DOC>NCT01266564</DOC>
	<brief_summary>This observational study will assess the progression-free survival, overall response and safety of Avastin (bevacizumab) in combination with chemotherapy in a real life setting in patients with metastatic colorectal cancer. Data will be collected from patients for approximately 2 years.</brief_summary>
	<brief_title>An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patients, age &gt;/=18 years Proven metastatic colorectal carcinoma Patients have measurable disease Patients are eligible to receive firstline Avastin Patients have signed data release form Contraindication to receive Avastin according to the local labeling Participation in a clinical study within 30 days prior to enrolment Patients have any other primary cancer Concomitant treatment with other biologics History of other malignant disease in the past 5 years except basal cell carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>